P2Y12抑制剂与脑出血住院患者死亡率的关系
P2Y12抑制剂单药和DAPT组严重卒中(NIHSS≥21)比例分别为26.8%和25.3%,高于阿司匹林单药20.5%和未用抗血小板药23.2%。风险调整后,与阿司匹林单药相比,P2Y12抑制剂单药和DAPT与严重卒中(AOR 1.43和1.40)及住院死亡(AOR 1.55和1.61)风险升高相关。阿司匹林单药与未用抗血小板药组住院结局无显著差异。
要点
- 与阿司匹林单药相比,ICH前使用P2Y12抑制剂单药与住院死亡风险升高相关(AOR 1.55,95%CI 1.46-1.66)。
- 与阿司匹林单药相比,ICH前使用DAPT(P2Y12抑制剂+阿司匹林)与住院死亡风险升高相关(AOR 1.61,95%CI 1.53-1.71)。
- P2Y12抑制剂单药和DAPT组严重卒中(NIHSS≥21)风险均高于阿司匹林单药(AOR分别为1.43和1.40)。
- 阿司匹林单药与未用抗血小板药的住院结局无统计学显著差异。
- P2Y12抑制剂组出院回家、独立行走和功能独立(mRS 0-2)的比例更低。
适用人群与场景
- 2013年1月至2021年12月期间因自发性脑出血住院的患者,数据来自Get With The Guidelines-Stroke注册研究。
- 抗血小板暴露定义为入院前7天内使用过任何抗血小板药物。
- 研究排除与抗凝相关的ICH(原文未提及具体排除标准细节)。
诊断标准与关键阈值
- 严重卒中定义为入院时NIHSS评分≥21分(NIHSS范围0-42,评分越高越严重)。
- 功能独立定义为出院时mRS评分0-2分。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- P2Y12抑制剂单药和DAPT组出院回家、独立行走和功能独立(mRS 0-2)的比例更低。
- 阿司匹林单药与未用抗血小板药组住院结局无统计学显著差异。
证据类型、等级与局限
- 证据类型:基于注册数据库的回顾性队列研究。
- 局限:观察性设计,可能存在残余混杂;抗血小板暴露依赖入院前7天用药记录;仅纳入参与Get With The Guidelines-Stroke的医院。
对床旁实践的改变
- 对于ICH患者,入院前使用P2Y12抑制剂(单药或联合阿司匹林)提示更严重卒中和更高住院死亡风险,应视为高危因素。
- 阿司匹林单药与未用抗血小板药的住院结局无显著差异,提示ICH前阿司匹林单药并非住院死亡的危险因素。
- 该研究为观察性设计,不能推断因果关系或改变抗血小板药物的常规使用指征。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although P2Y purinergic receptor 12 (P2Y12) inhibitors are commonly used in patients with atherosclerotic cardiovascular disease, there are limited data on intracerebral hemorrhage (ICH) associated with use of P2Y12 inhibitors.
OBJECTIVE: To compare stroke severity, in-hospital mortality, and functional outcomes in ICH among patients receiving P2Y12 inhibitor monotherapy, dual antiplatelet therapy (DAPT) with P2Y12 inhibitor plus aspirin, aspirin monotherapy, or no antiplatelet therapy prior to ICH.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study obtained data from the nationwide Get With The Guidelines-Stroke registry, which contains data from participating hospitals. Participants were patients hospitalized with spontaneous ICH between January 2013 to December 2021. The analysis was completed in January 2025.
EXPOSURES: Antiplatelet therapy before ICH, defined as any use within 7 days prior to hospital arrival.
MAIN OUTCOMES AND MEASURES: The primary outcomes were severe stroke at presentation and in-hospital mortality. Severity was assessed using the National Institutes of Health Stroke Scale (NIHSS; range: 0-42, with higher scores indicating greater severity), with a score of 21 or higher indicating severe stroke. Secondary outcomes included in-hospital mortality or discharge to hospice, discharge to home, independent ambulation, and modified Rankin Scale (mRS) score at discharge. An mRS score of 0 to 2 at discharge indicated functional independence.
RESULTS: Of the 252 691 patients included (median [IQR] age, 67 [56-78] years; 134 684 males [53.3%]), 6355 (2.5%) were receiving P2Y12 inhibitor monotherapy, 10 607 (4.2%) were receiving DAPT, 63 299 (25.0%) were receiving aspirin monotherapy, and 172 430 (68.2%) were receiving no antiplatelet agents prior to ICH. Patients taking P2Y12 inhibitors were older and had higher prevalence of cardiovascular risk factors. Overall, 1701 patients (26.8%) receiving P2Y12 monotherapy and 2688 patients (25.3%) receiving DAPT experienced severe ICH (NIHSS score ≥21) compared with 12 952 patients (20.5%) who used aspirin monotherapy and 39 970 (23.2%) patients who received no antiplatelet (P < .001). In-hospital mortality rates were highest in patients using DAPT (24.0%), followed by patients receiving P2Y12 inhibitor monotherapy (23.8%), no antiplatelet (16.8%), and aspirin monotherapy (16.5%) (P < .001). After risk adjustment, patients with prior use of P2Y12 inhibitors were more likely to present with severe stroke (P2Y12 inhibitor monotherapy: adjusted odds ratio [AOR], 1.43 [95% CI, 1.34-1.52]; P < .001; DAPT: AOR, 1.40 [95% CI, 1.33-1.47]; P < .001) and more likely to die in the hospital (P2Y12 inhibitor monotherapy: AOR, 1.55 [95% CI, 1.46-1.66]; P < .001; DAPT: AOR, 1.61 [95% CI, 1.53-1.71]; P < .001) compared with those using aspirin monotherapy. Furthermore, these patients were less likely to be discharged to home, be able to ambulate independently, or have functional independence at discharge. In contrast, there were no statistically significant differences in in-hospital outcomes between aspirin monotherapy and no antiplatelet therapy groups.
CONCLUSIONS AND RELEVANCE: In this registry-based cohort study of patients with ICH not associated with anticoagulation, P2Y12 inhibitors, either as monotherapy or in combination with aspirin, were associated with more severe stroke, in-hospital death, worse clinical outcomes, and reduced functional recovery compared with aspirin monotherapy or no antiplatelet therapy.
参考来源
- Jin C, Song Y, Mac Grory B, et al. P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage. JAMA Netw Open. 2026. PMID: 42424082. doi:10.1001/jamanetworkopen.2026.22239
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。